Literature DB >> 27626664

Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen Specific.

Lisa H Tostanoski1, Yu-Chieh Chiu1, Joshua M Gammon1, Thomas Simon2, James I Andorko1, Jonathan S Bromberg3, Christopher M Jewell4.   

Abstract

Many experimental therapies for autoimmune diseases, such as multiple sclerosis (MS), aim to bias T cells toward tolerogenic phenotypes without broad suppression. However, the link between local signal integration in lymph nodes (LNs) and the specificity of systemic tolerance is not well understood. We used intra-LN injection of polymer particles to study tolerance as a function of signals in the LN microenvironment. In a mouse MS model, intra-LN introduction of encapsulated myelin self-antigen and a regulatory signal (rapamycin) permanently reversed paralysis after one treatment during peak disease. Therapeutic effects were myelin specific, required antigen encapsulation, and were less potent without rapamycin. This efficacy was accompanied by local LN reorganization, reduced inflammation, systemic expansion of regulatory T cells, and reduced T cell infiltration to the CNS. Our findings suggest that local control over signaling in distinct LNs can promote cell types and functions that drive tolerance that is systemic but antigen specific.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CNS; autoimmunity; biomaterial; immune tolerance; lymph node; microparticle; multiple sclerosis; nanoparticle; regulatory T cell; vaccine

Mesh:

Substances:

Year:  2016        PMID: 27626664      PMCID: PMC5024722          DOI: 10.1016/j.celrep.2016.08.033

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  37 in total

Review 1.  Antigen-specific tolerization approaches in multiple sclerosis.

Authors:  Andreas Lutterotti; Roland Martin
Journal:  Expert Opin Investig Drugs       Date:  2013-10-23       Impact factor: 6.206

2.  Engineering antigens for in situ erythrocyte binding induces T-cell deletion.

Authors:  Stephan Kontos; Iraklis C Kourtis; Karen Y Dane; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

3.  Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis.

Authors:  Ada Yeste; Meghan Nadeau; Evan J Burns; Howard L Weiner; Francisco J Quintana
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-27       Impact factor: 11.205

Review 4.  Established and novel disease-modifying treatments in multiple sclerosis.

Authors:  A H Cross; R T Naismith
Journal:  J Intern Med       Date:  2014-03-11       Impact factor: 8.989

5.  Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation.

Authors:  Marianna Esposito; Francesca Ruffini; Matteo Bellone; Nicola Gagliani; Manuela Battaglia; Gianvito Martino; Roberto Furlan
Journal:  J Neuroimmunol       Date:  2010-02-11       Impact factor: 3.478

6.  A new strategy to determine the actual protein content of poly(lactide-co-glycolide) microspheres.

Authors:  H Sah
Journal:  J Pharm Sci       Date:  1997-11       Impact factor: 3.534

7.  In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles.

Authors:  Christopher M Jewell; Sandra C Bustamante López; Darrell J Irvine
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-06       Impact factor: 11.205

Review 8.  Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance.

Authors:  James I Andorko; Krystina L Hess; Christopher M Jewell
Journal:  AAPS J       Date:  2014-12-23       Impact factor: 4.009

9.  A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease.

Authors:  Zoe Hunter; Derrick P McCarthy; Woon Teck Yap; Christopher T Harp; Daniel R Getts; Lonnie D Shea; Stephen D Miller
Journal:  ACS Nano       Date:  2014-02-27       Impact factor: 15.881

10.  Intra-lymph node injection of biodegradable polymer particles.

Authors:  James I Andorko; Lisa H Tostanoski; Eduardo Solano; Maryam Mukhamedova; Christopher M Jewell
Journal:  J Vis Exp       Date:  2014-01-02       Impact factor: 1.355

View more
  59 in total

1.  An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.

Authors:  Jonathan J Cho; Joshua M Stewart; Theodore T Drashansky; Maigan A Brusko; Ashley N Zuniga; Kyle J Lorentsen; Benjamin G Keselowsky; Dorina Avram
Journal:  Biomaterials       Date:  2017-07-24       Impact factor: 12.479

2.  Lymph node fibroblastic reticular cells deposit fibrosis-associated collagen following organ transplantation.

Authors:  Xiaofei Li; Jing Zhao; Vivek Kasinath; Mayuko Uehara; Liwei Jiang; Naima Banouni; Martina M McGrath; Takaharu Ichimura; Paolo Fiorina; Dario R Lemos; Su Ryon Shin; Carl F Ware; Jonathan S Bromberg; Reza Abdi
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

3.  Use of Polymeric Nanoparticle Platform Targeting the Liver To Induce Treg-Mediated Antigen-Specific Immune Tolerance in a Pulmonary Allergen Sensitization Model.

Authors:  Qi Liu; Xiang Wang; Xiangsheng Liu; Sanjan Kumar; Grant Gochman; Ying Ji; Yu-Pei Liao; Chong Hyun Chang; Wesley Situ; Jianqin Lu; Jinhong Jiang; Kuo-Ching Mei; Huan Meng; Tian Xia; Andre E Nel
Journal:  ACS Nano       Date:  2019-04-12       Impact factor: 15.881

Review 4.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

5.  Engineering Biomaterials to Direct Innate Immunity.

Authors:  R S Oakes; E Froimchuk; C M Jewell
Journal:  Adv Ther (Weinh)       Date:  2019-02-27

Review 6.  Harnessing the lymph node microenvironment.

Authors:  Natalie A O'Neill; Haleigh B Eppler; Christopher M Jewell; Jonathan S Bromberg
Journal:  Curr Opin Organ Transplant       Date:  2018-02       Impact factor: 2.640

Review 7.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

8.  Designing inorganic nanomaterials for vaccines and immunotherapies.

Authors:  Krystina L Hess; Igor L Medintz; Christopher M Jewell
Journal:  Nano Today       Date:  2019-05-29       Impact factor: 20.722

9.  Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity.

Authors:  Krystina L Hess; James I Andorko; Lisa H Tostanoski; Christopher M Jewell
Journal:  Biomaterials       Date:  2016-11-30       Impact factor: 12.479

Review 10.  Engineering Immune Tolerance with Biomaterials.

Authors:  Joshua M Gammon; Christopher M Jewell
Journal:  Adv Healthc Mater       Date:  2019-01-03       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.